Caribou biosciences presents encouraging clinical data from cb-010 antler phase 1 trial in second-line lbcl patients at the 2024 american society of clinical oncology (asco) annual meeting

-- cb-010 allogeneic car-t cell therapy w ith partial hla matching has potential to rival efficacy and safety profile of approved autologous car-t cell therapies -- -- 14.4 months median pfs in antler patients with partial hla matching (≥4 alleles) --
CAR Ratings Summary
CAR Quant Ranking